Cryo-EM. We isolated full-length human LAT1-CD98hc by using mammalian overexpression and affinity purification, and validated The L-type amino acid transporter 1 (LAT1 or SLC7A5) transports large neutral amino acids across the membrane and is crucial for brain drug delivery and tumor growth. LAT1 forms a disulfide-linked heterodimer with CD98 heavy chain (CD98hc, 4F2hc or SLC3A2), but the mechanism of assembly and amino acid transport are poorly understood. Here we report the cryo-EM structure of the human LAT1-CD98hc heterodimer at 3.3-Å resolution. LAT1 features a canonical Leu T-fold and exhibits an unusual loop structure on transmembrane helix 6, creating an extended cavity that might accommodate bulky amino acids and drugs. CD98hc engages with LAT1 through the extracellular, transmembrane and putative cholesterol-mediated interactions. We also show that two anti-CD98 antibodies recognize distinct, multiple epitopes on CD98hc but not its glycans, explaining their robust reactivities. These results reveal the principles of glycoprotein-solute carrier assembly and provide templates for improving preclinical drugs and antibodies targeting LAT1 or CD98hc.
H umans possess more than 65 amino acid transporters, which belong to 11 discrete solute carrier (SLC) families 1 . The heteromeric amino acid transporters (HATs or SLC3 and SLC7 families) are unique SLC transporters composed of two subunits, the light chain (SLC7) and the heavy chain (SLC3), linked by a conserved disulfide bridge [2] [3] [4] . The light chain is a 12-spanning membrane protein belonging to the amino acidpolyamine-organocation transporter (APC) superfamily 5 , whereas the heavy chain is a type-II membrane glycoprotein that facilitates heterodimer trafficking 6 . The human genome contains eight SLC7 members (SLC7A5-11, 13), which specifically associate with one of two SLC3 members (SLC3A1 and 2), giving rise to eight HAT subtypes 7 . The L-type amino acid transporter 1 (LAT1 or SLC7A5) is a Na + -independent amino acid antiporter with broad substrate specificity towards large neutral amino acids, such as Leu, Tyr and Trp 8 . LAT1 also transports amino acid derivatives, such as thyroid hormones 9 , l-DOPA 10 , melphalan 11 and gabapentine 11 . Highly expressed in immune T cells 2, 12 , the blood-brain barrier 13 and various cancers 8, 14, 15 , LAT1 is an important target for cancer diagnosis and treatment [16] [17] [18] and the development of novel blood-brain barriercrossing drugs 19 . In addition, uptake of Leu by LAT1 is essential for mTOR activation 20 . LAT1 forms a disulfide-linked heterodimer with CD98 heavy chain (CD98hc, 4F2hc or SLC3A2) 2 , which is a multifunctional protein implicated in amino acid transport, cell adhesion 21 and immune activation 22 .
Despite its biological importance, our understanding of the molecular assembly and transport mechanisms of LAT1-CD98hc is limited. Previous studies on the bacterial SLC7 homologs, ApcT 23 and AdiC [24] [25] [26] [27] , have provided the basis to understand the amino acid transport mechanism by the light chain. In addition, the crystal structure of an isolated extracellular domain of CD98hc has revealed its glucosidase-like fold 28 . However, many questions remain unanswered. How do the heavy chain and the light chain interact with each other? How can LAT1 recognize a broad range of substrates, while its bacterial homologs cannot? What is the functional role of the single transmembrane domain of CD98hc? What are the structure-function relationships of SLC3-and SLC7-related genetic diseases [29] [30] [31] [32] [33] ? These questions can only be answered by studying LAT1-CD98hc in its full heterodimeric assembly.
In this study, we used cryo-EM to reveal the molecular architecture and transport mechanisms of the human LAT1-CD98hc complex. On the basis of the structures of LAT1-CD98hc bound to one or two monoclonal antibodies, we defined the mechanisms for heterodimer assembly and antibody targeting of LAT1-CD98hc, and obtained insights into its putative substrate-binding modes. These results provide a framework to address many of the unanswered questions about this unique solute carrier-glycoprotein complex.
its biochemical function by using proteoliposomes ( Supplementary  Fig. 1a-g ). LAT1-CD98hc is a relatively small (~125 kDa) membrane protein without symmetry, which makes it a challenging target for cryo-EM 34 . To increase the particle size and add features for image alignment 35 , we utilized commercial anti-CD98 antibodies. A screening identified two mouse monoclonal antibodies, clones HBJ127 and MEM-108, as promising candidates (Supplementary Fig. 1h,i ; also see Methods). These antibodies were raised against human cancers, and HBJ127 is known to have strong antitumor activity 36 . Initial cryo-EM imaging of the Fab-bound LAT1-CD98hc complexes indicated that MEM-108 is more rigidly bound than HBJ127, suggesting its superior property as a structural marker ( Supplementary Fig. 1i ). We recorded 3,382 micrographs of the LAT1-CD98hc-MEM-108 Fab complex on a 300 kV Titan Krios microscope, and the final three-dimensional (3D) reconstruction yielded a map with the global resolution of 3.31 Å, according to the Fourier shell correlation (FSC) = 0.143 criterion (Table 1 and Supplementary Note 1).
The EM map resolved all of the protein components, including the extracellular domain (ED) of CD98hc, its single transmembrane helix (TM1′), 12 transmembrane helices of LAT1 (TM1-TM12) and MEM-108 Fab, in addition to glycans and lipids ( Fig. 1a and Supplementary Fig. 2a ). The local resolution analysis indicated a better resolution at the CD98hc-ED, which was around 3.1 Å, compared with the TMs and Fab, where the resolution varied from 3.1 to 3.9 Å in the core and from 3.9 to 4.6 Å in the periphery (Supplementary Note 1). We built atomic models of all TMs and most loops of LAT1 and CD98hc de novo ( Supplementary  Fig. 2a ,b and Supplementary Video 1) and fitted the crystal structure of CD98hc-ED 28 as an initial model. Since the sequence of MEM-108 is not publicly available, its six complementarity-determining regions (CDRs) were modeled as polyalanine.
Architecture of LAT1-CD98hc. The cryo-EM structure of LAT1-CD98hc revealed the hitherto unobserved architecture of a transporter-glycoprotein heterocomplex (Fig. 1a) . The large extracellular domain (ED) of the glycoprotein CD98hc sits on top of the transmembrane domain (TMD) of LAT1, connected by a short linker that forms the intermolecular disulfide bond (Fig. 1a) . On the extracellular side, the ED of CD98hc is positioned above LAT1 with an ~20-Å shift from the center (Fig. 1b) , and its orientation agrees with the previous crosslinking data and the 3D reconstructions from LAT2-CD98hc 37, 38 ( Supplementary Fig. 3a ). The surface electrostatic potential calculation showed that the LAT1-facing surface of CD98hc is positively charged, whereas the corresponding surface of LAT1 is negatively charged, indicating electrostatic interactions ( Supplementary Fig. 3b ). Within the lipid bilayer, a single transmembrane helix of CD98hc (TM1′) is positioned adjacent to the TMD of LAT1 (Fig. 1a) . We observed five flat-shaped densities at this interface, which could be best modeled as cholesterols (Fig. 1a,b and Supplementary Fig. 2a,b ; discussed in the section 'Structure of glycosylated, full-length CD98hc'). MEM-108 Fab binds to CD98hc-ED on the opposite side of the LAT1-CD98hc interface, extending towards the extracellular space by about 40 Å (Fig. 1b) .
Structure of LAT1.
We first turned to LAT1, the functional transport unit of the heterodimer 39 . LAT1 has 12 TMs, including the ten core TMs with a '5 + 5' inverted repeat topology 5 , plus TM11 and TM12 (Fig. 2a) . As in other APC members 40 , the ten core TMs can be grouped into three functional subdomains, named hash (TMs 3, 4, 8 and 9), bundle (TMs 1, 2, 6 and 7) and arms (TMs 5 and 10) ( Supplementary Fig. 4a,b) . On the extracellular side, LAT1 has six extracellular loops (EL1-6), and the intracellular side has five intracellular loops (IL1-5) and the amino and carboxy termini (Fig. 2a) . Most of these loops are resolved in the cryo-EM map, and EL2 folds into a structured loop, EL4 forms two short helices (EL4a and EL4b) and IL1 forms one short helix ( Fig. 2a and Supplementary Fig. 4a,b) .
In the bundle domain, TM1 and TM6 are each divided into two discontinuous helices, TM1a and TM1b and TM6a and TM6b (Fig. 2b) . The structure showed that TM1a and TM6b swing towards the lipid bilayer, forming a solvent-exposed cavity towards the cytoplasmic side (Fig. 2b) . This cavity is lined by numerous hydrophilic residues, creating a putative substrate passageway ( Supplementary  Fig. 4c,e) . This region forms a cytoplasmic gate in the bacterial APC transporters 40 , and thus in the current LAT1 structure the cytoplasmic gate is open ( Supplementary Fig. 4c ).
At the end of the cavity is a conserved substrate-binding site shared by all characterized APC transporters 41 . The structure revealed an empty space without any prominent density (Fig. 2b,c and Supplementary Fig. 2c ), indicating the apo state of the transporter. One side of this pocket is surrounded by hydrophobic residues, such as Phe 252, Trp 257 and Trp 405 (Fig. 2c) , and the extracellular side is sealed by numerous residues on TM1b, TM3, TM6a and TM10, which form an extracellular gate 41 ( Fig. 2a and Supplementary Fig. 4c,d ). The extracellular gate is further sealed by EL4a (Supplementary Fig. 4a ). Above the extracellular gate is a vestibule surrounded by numerous charged residues on LAT1 and CD98hc ( Supplementary Fig. 3b ), which may provide a favorable environment for substrate recruitment when the extracellular gate is open. Overall, our structure captures LAT1 in the inward-open state, which features a large, hydrophobic cavity in the putative substrate-binding site.
Large, neutral substrate-binding site. An important hallmark of LAT1 is its wide substrate specificity towards bulky hydrophobic amino acids and analogs 9, 11 . To understand the broad substrate specificity, we compared the substrate-binding site of LAT1 with those of the bacterial SLC7 homologs, GkApcT 23 and EcAdiC 25, 26 . These members share 25.4% and 20.3% sequence identities with LAT1, respectively, but they transport smaller amino acids, such as Ala and Arg. The structural comparison revealed that the TM1a-TM1b loop is almost identical between the three members, with the conserved the G(S/T)G motif in the middle ( Supplementary Fig.  4f,g ). In ApcT and AdiC, this G(S/T)G motif creates a loop structure, which exposes the backbone amide groups to the solvent and provides hydrogen-bond donors to the substrate carboxyl group 25 . In our structure of LAT1, 65 
GSG
67 formed a similar loop structure, exposing the amide group of Ser 66 towards the empty space (Figs. 2c and 3a) , suggesting a similar manner of substrate carboxyl recognition, which has been proposed previously 42 . In addition, the electropositive potential from the helix dipole of TM1b would provide a favorable interaction with the electronegative substrate carboxyl group (Fig. 3a) .
In contrast to the TM1a-TM1b loop, the TM6a-TM6b loop is only partly conserved. The loop starts with the conserved F/W motif ( Supplementary Fig. 4g ), and its main chain carbonyl provides a hydrogen-bond acceptor for the substrate amide group in ApcT and AdiC 23, 25, 27 . In addition, the aromatic group of the F/W motif forms a hydrophobic interaction with the substrate Cβ atom. This structure is conserved in LAT1, and thus can provide similar backbone amide and Cβ recognition sites (Fig. 2c) . However, three residues after Phe 252, there is Gly 255 in LAT1 instead of Ile in ApcT and AdiC, which would form a sidewall to restrict the conformational freedom of the substrate side chain ( Fig. 3a-c) . Consequently, in LAT1 the TM6a-TM6b loop falls apart from TM10 and creates an additional pocket (named the distal pocket; Fig. 3a and Supplementary  Fig. 4f ). The distal pocket is ~17 Å long and ~14 Å wide and surrounded by a cluster of hydrophobic residues (Leu 251, Trp 257, Trp 405 and Val 408) (Fig. 3a) , and thus is suitable for accommodating bulky hydrophobic side chains. Interestingly, this pocket is offset by ~60° from the direction of the substrate Arg side chain in ApcT or AdiC (Fig. 3a-c) . Thus, the substrates must be kinked to fit into the whole pocket, which may explain why LAT1 favors meta substitutions on the primary phenyl ring of the substrates [43] [44] [45] .
To examine the functional importance of the key residues for substrate binding, we generated single-point mutants of these residues and measured their Leu transport activities in Xenopus laevis oocytes 8 ( Supplementary Fig. 5a -e). Mutations in the GSG motif (G65A, S66V, S66N and G67A on TM1) strongly reduced the uptake of Leu (Fig. 3d) , consistent with their suggested role in substrate backbone recognition (Figs. 2c and 3a-c). F252A (TM6) also showed reduced uptake ( Fig. 3d) , probably reflecting the loss of the interaction between its aromatic group and the substrate Cβ atom (Fig. 2c) . In contrast, the G255A mutation, which adds a methyl group near the proximal pocket ( Fig. 3a) , had minimal effect on the Leu transport (Fig. 3d) . We reasoned that this substitution is tolerable for small amino acids. To further characterize G255A, we measured the transport activities for various amino acids, and found reduced transport for larger amino acids, Trp and Tyr, whereas transport of Leu and Phe was not affected severely ( Fig. 3e) , supporting a role for Gly 255 in the recognition of bulky side chains. Interestingly, G255A showed increased transport for Ala and Val, which were not readily transported by the wild type ( Fig. 3e and Supplementary Fig. 5b,c) , suggesting that the added methyl group of G255A enabled favorable interaction with the small methyl group(s) of Val and Ala. Together, these results confirm the critical roles of the GSG motif and Phe 252 in the substrate transport and the role of Gly 255 in biasing the substrate specificity towards large amino acids.
Structure of glycosylated, full-length CD98hc. The structure of full-length CD98hc revealed the previously uncharacterized features of this glycoprotein 28 . Full-length CD98hc consists of four regions, the N-terminal cytoplasmic tail, the single transmembrane domain (TM1′), the domain linker and the extracellular domain (ED) ( Supplementary Fig. 6a,b) . The ED spans residues 215-630, consisting of eight (β/α) repeats (domain A) and eight antiparallel β sheets (domain C), and superimposes well on the previous crystal structure 28 ( Supplementary Fig. 6a ). The cryo-EM map revealed the presence of four glycans, attached to Asn 365′, Asn 381′, Asn 424′ and Asn 508′ on domain A, in agreement with predicted N-glycosylation 46 ( Supplementary Fig. 2a ). All glycans are located distal from the CD98hc-LAT1 interface (Fig. 1b) , confirming that glycosylation is not directly involved in heterodimer formation 47 . The transmembrane domain of CD98hc (TM1′) spans residues 185-205, forming a helix-helix contact with TM4 ( Supplementary  Fig. 7a,b) . We found four sterol molecules bound to this interface from the outer leaflet (Fig. 1a,b and Supplementary Fig. 6d ), which may explain the observation that cholesterol and its analogs increase the stability of LAT2-CD98hc 48 . In contrast to the extensive interactions in the outer leaflet, there is almost no direct contact between TM1′ and TM4 in the inner leaflet ( Supplementary  Fig. 7a,b) . This is apparently due to the mismatch of the bulky residues, Phe 189′, Trp 190′ and Phe 193′ of CD98hc and Leu 180 and Leu 181 of LAT1, which push TM1′ away from TM4 in the middle, creating an ~10-Å gap in the inner leaflet (Supplementary Fig. 7b ). We found one sterol density in this gap, which probably stabilizes the interface by compensating for the absence of direct interactions ( Supplementary Fig. 6d ).
The ED and TM1′ are connected by a short linker referred to as the 'neck' 49 , which was not resolved in the previous structure of isolated CD98hc-ED 28 . Strikingly, this linker is ordered in our structure of LAT1-CD98hc, forming an extended ~33-Å loop bridging the ED and TM1′ (Supplementary Fig. 6c ). Almost all of the residues in this linker participate in stabilizing interactions: Cys 210′ forms a disulfide bridge with Cys 164 of LAT1, the Arg 211′ side chain forms an intramolecular salt bridge with Glu 539′, the Arg 211′ main chain hydrogen bonds to Asp 558′ and Thr 163 (LAT1), Val 213′ and Pro 214′ form van der Waals interactions with Trp 557′ and His 538′, and Arg 206′ and Arg 209′ interact with the interfacial sterols ( Supplementary Fig. 6c) . Therefore, the linker of CD98hc is an integral part of the heterodimer structure rather than just a connecting peptide 49 .
The long cytosolic N-terminal tail (~180 residues in isoform c) is not resolved in our structure, indicating its high degree of flexibility. Since the N-terminal tail has been implicated in binding with other interaction partners 50 , this flexibility may provide conformational freedom for potential interaction with these proteins. In addition, the loose packing of TM1′ to TM4 in the cytoplasmic half may allow the N-terminal tail to remain flexible even when CD98hc is associated with LAT1 ( Supplementary Fig. 7b ).
Heavy-light chain interface. Human CD98hc reportedly associates with six SLC7 light chains, LAT1, LAT2, y + LAT1, y + LAT2, xCT and asc-1 (ref. 51 ). To understand the structural basis of these multispecific heterodimerizations, we analyzed the interface between CD98hc and LAT1 in more detail and compared their sequences with those of other SLC3-SLC7 pairs ( Supplementary Fig. 7b-h ).
There are four interfaces between the heavy chain and the light chain: TM1′-TM4, linker-Cβ2-Cβ3-Cβ8-EL2, Aα8-EL4a and Aα1-Aα2-EL3 ( Supplementary Fig. 7a-d) . The TM1′-TM4 interface consists of hydrophobic packing between Ile 203′, Ala 200′, Met 196′ and Leu 197′ on CD98hc and Ala 170, Leu 173, Val 174 and Leu 177 on LAT1 (Supplementary Fig. 7b ). These hydrophobic residues on TM4 are well conserved in the six human light chains associated with CD98hc ( Supplementary Fig. 7e) , and probably favor similar helixhelix packing interactions. The linker-Cβ2-Cβ3-Cβ8-EL2 interface involves the disulfide bridge (Cys 210′ and Cys 164) and hydrogen bond (Arg 511′ and Thr 163), and is mediated by several direct or indirect interactions (Supplementary Fig. 7c ). Although it is not strictly conserved, EL2 of all light chains exhibits shared features: it is nine residues long, it starts and ends with two conserved Pro residues (Pro 159 and Pro 167), Phe or Tyr is at the third position and a hydrophilic residue is at the fifth position (Supplementary Fig. 7e ). These features probably enable EL2 to adopt a similar conformation in all SLC7 light chains, allowing similar interactions. In stark contrast, the cationic amino acid transporters (SLC7A1-4), which do not associate with SLC3 (ref. 39 ), do not share these features in EL2. The Aα8-EL4a interface consists of two pairs of hydrophilic residues, Lys 532′ and Arg 534′ on CD98hc and Glu 303 and Gln 304 on LAT1, which participate in ionic and hydrogen-bonding contacts (Supplementary Fig. 7d ). Although not strictly conserved, at least one charged residue is found on EL4a of all light chains, suggesting that EL4a can form an equivalent electrostatic interaction with Aα8 ( Supplementary Fig. 7g ). The Aα1-Aα2-EL3 interface is only partly resolved in our cryo-EM map, but there are charged residues on EL3 ( Supplementary Fig. 7f ), which can form ionic interactions with the surface-exposed residues Lys 255′, Lys 299′ and Lys 300′ on CD98hc. Overall, these interfaces together contribute to the stable interaction of the heterodimer, and there is no single residue that would dictate the heterodimerization in all SLC7 members, except for the conserved Cys. This may explain the previously puzzling observation that the critical regions for heterodimer formation vary among the different SLC7 light chains 52 . Notably, all of the aforementioned traits of the SLC7 light chains are also conserved in b 0,+ AT and AGT-1 ( Supplementary Fig. 7e-g ), which associate with another SLC3 member rBAT (SLC3A1) 30, 53 . This might imply that the association of these two light chains with rBAT is governed by different principles, such as localization or expression patterns 31 . Meanwhile, a sequence comparison between rBAT and CD98hc revealed that the linker of rBAT is five residues shorter than that of CD98hc ( Supplementary Fig. 7h) , and thus the linker in rBAT cannot form an extended structure as in CD98hc. With such a short linker, the orientation of the ED of rBAT will differ from that in the LAT1-CD98hc heterodimer, and thus b 0,+ AT-or AGT-1-rBAT may have a different interface.
Anti-CD98 antibodies and epitopes.
CD98hc is a promising target for therapeutic antibodies in cancer therapy, and HBJ127 and other antibodies indeed have antitumor activity 54 . During our efforts to identify suitable antibodies for cryo-EM, we found that HBJ127 binds to a different epitope from that of MEM-108. To gain further insights into the different antibody-targeting mechanisms, we determined the structure of the CD98hc-ED bound to both HBJ127 Fab and MEM-108 Fab at 4.1-Å resolution (Fig. 4a,b and Supplementary Note 2; see Methods for details). Consistent with their non-competitive binding modes, HBJ127 and MEM-108 recognize different epitopes (Fig. 4c) . The epitope of MEM-108 involves four discontinuous sequences 410-413, 547-549, 571-575 and 617-619, which are close together in the three-dimensional structure (Fig. 4c) . The paratope of MEM-108 consists of CDR-H1, -H2, -H3, -L1 and -L3, which clamp the four loops of CD98hc (Fig. 4e) . A local resolution analysis revealed that this antibody interface is the most ordered part of our cryo-EM map, suggesting a rigid interaction between MEM-108 and CD98hc (Supplementary Note 2) . This robust binding mode of MEM-108 suggests its potential therapeutic use.
The epitope of HBJ127 involves residues 476-483 and 497-501, which are unexpectedly different from the previous data obtained from fragment-based phage-display screening 55 ( Fig. 4c) . Residues 476-483 are recognized by CDR-H2 and -H3, and residues 497-501 are recognized by CDR-L1 and -L3, involving ionic, hydrophilic and hydrophobic interactions (Fig. 4d) . A previous study showed that HBJ127 does not react with mouse or rat CD98hc 55 , which can be rationalized by the different sequences in the second epitope loop of CD98hc (residues 497-501 in human) (Supplementary Note 2). In addition, the structure shows that HBJ127 only recognizes the peptide regions and not the glycans, explaining why it can robustly target various cancer cell lines that have different CD98 glycoforms 47 .
Our structure showed that these two antibodies neither disturb the structural integrity of the ED nor break the heterodimer interface. This supports the idea that most anti-CD98 antibodies act through antibody-dependent cellular cytotoxicity 54 , rather than by inhibiting amino acid transport per se. Nonetheless, these antibodies may still block the binding of known partners to the ED 56, 57 . The recently characterized humanized antibody IGN523 exhibits robust antitumor activity through antibody-dependent cellular cytotoxicity 54 , and its epitopes are predicted to be different from those presented here. Further structural studies will clarify how different antibodies exert their distinct mechanisms of action through CD98.
Discussion
The structure of LAT1-CD98hc revealed that its putative substratebinding site consists of three structural elements: (1) the positive and negative poles of the two short helices that can recognize the substrate carboxyl and amino moieties, (2) the proximal pocket that can accommodate primary side chains and (3) the distal pocket that provides a promiscuous binding site for hydrophobic secondary substitutions. This configuration is in striking agreement with previous hypotheses derived from pharmacophore prediction 44 , homology modeling 58 and structure-function analyses 11 . We anticipate that our structure of LAT1-CD98hc will enable more detailed investigations into the ligand-binding modes.
The substrate transport mechanism in the APC superfamily has been well established from studies on prokaryotic members 40 . The general model is called the 'rocking bundle' mechanism, in which TM1a, TM1b, TM6a and TM6b undergo a series of conformational changes to transport substrates 59 . The structure of LAT1 confirmed that this eukaryotic APC member shares the same global architecture and functional elements as its prokaryotic counterparts, and is thus likely to follow the same rocking bundle mechanism of amino acid transport (Fig. 5a,b) . In the present structure, the rocking bundle is ready to accept a substrate from the cytosolic solvent (Fig. 5a) . Substrate binding causes the reorientation of the helix backbones of TM1a and TM6b and, eventually, their major movements, leading to an occluded state. A possible deviation from the general model is that CD98hc-ED is on top of LAT1, and contacts EL4a. In most APC members, EL4 has been implicated in the latch function 41 , where it opens and closes in the transport cycle. Therefore, EL4a of LAT1 may rearrange its interaction with CD98hc to widen the substrate pathway in an outward-open state (Fig. 5b) .
During the revision of this manuscript, another group reported the structures of human LAT1-CD98hc in the apo and inhibitorbound states 60 . Although the overall structures superimpose well with the one presented here, those structures resolved additional cytoplasmic helices in LAT1 and CD98hc, which form critical heterodimer interfaces. We did not observe these helices here, perhaps due to the different sample preparation or the image alignment bias with Fab. Nonetheless, both studies support the same conclusions for the heterodimer architecture and putative substrate-binding site of LAT1-CD98hc.
In summary, the cryo-EM structure of LAT1-CD98hc offers a first glimpse into the organization of the unique glycoprotein-solute carrier complex. The structure of the putative substrate-binding pocket of LAT1 enables re-analysis of the vast amount of structureactivity correlation data available on its substrates and inhibitors. The finding that CD98hc associates with LAT1 through multiple interactions will prompt future structure-based experiments to examine which interactions play major roles in other SLC3-SLC7 pairs. An unanswered question is how other partner proteins, such as integrins 21 , interact with CD98hc.
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Methods
Expression and purification of the LAT1-CD98hc heterodimer. The sequences encoding full-length human LAT1 (SLC7A5; UniProt ID Q01650) and CD98hc isoform c (SLC3A2 isoform 1; UniProt ID P08195-1) were amplified from human universal reference complementary DNA (Zyagen) and cloned individually into the pEG BacMam vector 61 . LAT1 was fused with the C-terminal FLAG epitope and CD98hc was fused with the N-terminal His 8 tag and enhanced green fluorescent protein (eGFP), followed by the tobacco etch mosaic virus (TEV) protease cleavage site. Baculoviruses were generated in Spodoptera frugiperda Sf9 cells using the Bac-to-Bac system (Invitrogen). For expression, HEK293S GnTI − cells were cultured in suspension in FreeStyle 293 medium (Gibco) supplemented with 2% fetal bovine serum. The two separate P2 baculoviruses were added at a ratio of 1:1 (v/v) at a cell density of 3-4 × 10 6 cells per ml. The total amount of baculovirus added was ~10% (v/v) of the HEK293S GnTI − culture. To boost overexpression, sodium butyrate was added at a final concentration of 5-10 mM. Cells were cultured at 37 °C for 12 h after infection, and then at 30 °C for another 48 h. Cells were collected by centrifugation at 5,000g for 12 min, resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl and protease inhibitors) and disrupted by probe sonication for 5 min. The lysate was subjected to ultracentrifugation at 138,000g for 70 min, and the membrane pellet was resuspended in lysis buffer, homogenized in a glass homogenizer and stored at −80 °C.
All purification procedures were performed at 4 °C. The membrane fraction was solubilized in solubilization buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.5% dodecyl maltoside (DDM), 0.3% cholesteryl hemisuccinate (CHS) and protease inhibitors) for 90 min with gentle stirring. After removing the insoluble material by ultracentrifugation at 138,000g for 32 min, the supernatant was incubated with ANTI-FLAG M2 Affinity Agarose Gel (Sigma) for 90 min. The gel was poured into an open column and washed with ten column volumes of wash buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% DDM and 0.01% CHS). The detergent was replaced with digitonin by washing the gel with three column volumes of digitonin buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl and 0.1% digitonin) and the protein was eluted by adding 100 μg ml −1 Flag peptide. The eluted fraction contained mostly LAT1-CD98hc but also contained free LAT1 and other unidentified proteins. To achieve a more homogeneous preparation, we performed another round of purification by using a GFP-nanotrap 62 . The GFP-nanotrap affinity resin was prepared as described previously 63 . Briefly, an anti-GFP nanobody known as an enhancer 63 was expressed in the Escherichia coli BL21 strain with an N-terminal PelB signal and a C-terminal His 8 tag and purified by immobilized metal affinity chromatography. The purified nanobody was then coupled to CNBr-Activated Sepharose 4 Fast Flow beads (GE Healthcare) to yield the GFP-nanotrap, with ~1 mg coupled protein per ml swelled resin. The Flag eluate containing the LAT1-CD98hc complex (with His 8 -eGFP tag on CD98hc) was reacted with the GFP-nanotrap for 90 min and washed with ten column volumes of digitonin buffer. The LAT1-CD98hc complex was cleaved off from the column by digestion with TEV protease for 16 h. The eluate was concentrated with a 100-kDa molecular weight cut-off (MWCO) concentrator (Merck Millipore) to ~3 mg ml −1 , as calculated from the A 280 absorbance assuming that the extinction coefficient of the heterodimer was 1.33. The concentrated sample was loaded onto a Superose 6 Increase 10/300 column equilibrated with digitonin buffer. The peak fractions containing the LAT1-CD98hc heterodimer were collected and concentrated to ~2 mg ml −1 ( Supplementary Fig. 1a,b) . The purified LAT1-CD98hc was aliquoted and stored at −80 °C.
Transport assays in proteoliposomes.
The purified LAT1-CD98hc was reconstituted in liposomes at a protein-to-lipid ratio of 1:120 (w/w) by the polystyrene beads and dialysis method (modified from ref. 64 ). The liposomes, composed of a 5:1 (w/w) ratio of l-α-phosphatidylcholine type II-S (Sigma) to brain total lipid extract (Avanti Polar Lipids), were prepared as described 53 . The purified proteins were mixed with Triton X-100 (0.11% w/v)-destabilized liposomes, which were extruded through a 100-nm polycarbonate filter in reconstitution buffer containing 50 mM Tris-HCl (pH 7.0) and 100 mM KCl. The detergents were then removed by stepwise additions of Bio-bead SM2 resin (Bio-Rad), followed by 16 h of dialysis in a 10,000 MWCO regenerated cellulose membrane (Spectrum) against the reconstitution buffer. The proteoliposomes were concentrated by centrifugation at 415,000g for 1 h and flash frozen at −80 °C until use. Empty liposomes were prepared in the same way using washing buffer instead of the purified proteins. The transport assay was performed, on the basis of previous experiments with another heterodimeric amino acid transporter 53 . Briefly, the uptake reaction was initiated by a 40-fold dilution of the proteoliposomes (~4-5 µg protein per ml) into the reconstitution buffer containing the indicated concentration of radioisotope-labeled substrates (10 )). The reaction was terminated by the addition of ice-cold reconstitution buffer and filtered through a 0.45-µm nitrocellulose filter (Millipore), followed by washing with the same buffer. The membranes were soaked in Clear-sol I (Nacalai Tesque) and the radioactivity on the membrane was monitored with a β-scintillation counter (LSC-8000, Hitachi). For the time course experiments, before the transport assay, the proteoliposomes or empty liposomes were mixed with 4 mM l-glutamine for 3 h on ice, precipitated by ultracentrifugation and then resuspended in the reconstitution buffer. For the competitive inhibition assay shown in Supplementary  Fig. 1f , competitive inhibitors were added in the external solution at the same time. For the inhibition assay shown in Supplementary Fig. 1g , liposomes were pre-incubated with indicated inhibitors for 10 min and the uptake of l-[ 3 H] Tyr (100 μM) was measured. In all experiments, empty liposomes were used to determine the background, which was subtracted from the proteoliposome signal. Experiments were performed independently 2-4 times using the different lots of proteoliposomes, and the results showed good reproducibility.
Screening of antibodies for cryo-EM. Anti-CD98 or -LAT1 monoclonal antibodies were purchased from various commercial sources. To screen for structure-recognition antibodies, the binding properties of individual antibodies to LAT1-CD98hc were compared between native and denatured conditions. For the native conditions, purified LAT1-CD98hc was mixed with the antibody in digitonin buffer, at a molar ratio of 1:1.5, and subjected to analytical size-exclusion chromatography on a Superdex 200 Increase 10/300 column. Antibody binding was assessed by monitoring the peak shift from the peak of LAT1-CD98hc. Five positive candidates identified in this assay were subjected to a negative screening by using western blotting under denaturing conditions. Purified LAT1-CD98hc was mixed with SDS-PAGE sample buffer containing 10% SDS and 20% (v/v) β-mercaptoethanol and fractionated on the SDS-PAGE gel. The proteins were blotted with each antibody and then with corresponding secondary antibody. Among the four negative candidates that gave no detectable bands, two antibodies (clones MEM-108 and HBJ127) were selected for the current study.
For cryo-EM applications, the antibodies were digested into Fab fragments by using an IgG 1 Fab preparation kit (Pierce), according to the manufacturer's protocol. The purified Fabs were concentrated to approximately 1.5 mg ml −1 and buffer exchanged into digitonin buffer. For complex formation, purified LAT1-CD98hc was mixed with the Fab at a molar ratio of 1:1.2 for 1 h, and then loaded onto a Superdex 200 Increase 10/300 column equilibrated in digitonin buffer. Peak fractions containing the LAT1-CD98hc-Fab complex were concentrated to ~5.3 mg ml −1 with a 30-kDa MWCO concentrator and used immediately for cryo-EM grid preparation.
Sample vitrification and cryo-EM data acquisition. The purified LAT1-CD98hc-MEM-108 Fab (3 μl at 5.3 mg ml ) was applied onto a freshly glow-discharged Quantifoil holey carbon grid (R1.2/1.3, Cu, 300 mesh), blotted for 10 s at 6 °C in 100% humidity and plunge-frozen in liquid ethane by using Vitrobot Mark IV. Vitrification of Fab-free LAT1-CD98hc, LAT1-CD98hc-HBJ127 Fab and LAT1-CD98hc-HBJ127 Fab-MEM-108 Fab was performed with similar procedures but using different optimized sample concentrations (5.0-7.0 mg ml −1 ) and blotting times (8-12 s). Initial cryo-EM screening was performed on a 200 kV JEM 2010F microscope (JEOL) equipped with a FastScan-F114F charge-coupled device camera (TVIPS). Imaging was performed at a nominal magnification of ×80,000, resulting in a pixel size of 1.12 Å per pixel. Micrographs were recorded with an exposure time of 1-2 s, with a defocus range of −1.0 to −2.0 μm. Particles were picked in RELION-2.1 and analyzed in cryoSPARC 65 . High-resolution cryo-EM imaging of the LAT1-CD98hc-MEM-108 Fab complex was performed on a 300 kV Titan Krios G3i microscope (Thermo Fisher Scientific) equipped with a GIF Quantum energy filter (Gatan) and a Falcon III direct electron detector (Thermo Fisher Scientific) in the electron counting mode. Imaging was performed at a nominal magnification of ×96,000, corresponding to a calibrated pixel size of 0.8346 Å per pixel. Each movie was recorded for 46.5 s and subdivided into 60 frames. The electron flux rate was set to 0.73 e − per pixel per second at the detector, resulting in an accumulated exposure of 46.0 e − /Å 2 at the specimen. The data were automatically acquired using the EPU software, with a defocus range of −1.5 to −2.5 μm. A total of 3,482 movies were recorded in two separate sessions.
High-resolution cryo-EM imaging of the LAT1-CD98hc-HBJ127 Fab-MEM-108 Fab complex was performed on a 200 kV Tecnai Arctica microscope (FEI) equipped with a K2 Summit direct electron detector (Gatan) in the super-resolution mode. Imaging was performed at a nominal magnification of ×23,500, corresponding to a calibrated pixel size of 1.49 Å per pixel. Each movie was recorded for 15.6 s and subdivided into 40 frames. The electron flux rate was set to 7.14 e − per pixel per second at the detector, resulting in an accumulated exposure of 50.2 e − /Å 2 at the specimen. The data were automatically acquired using the SerialEM software 66 with a defocus range of −0.5 to −1.5 μm.
Image processing. For the LAT1-CD98hc-MEM-108 Fab dataset, dosefractionated movies were subjected to beam-induced motion correction using MotionCor2 (ref. 67 ), and the contrast transfer function (CTF) parameters were estimated using CTFFIND4 (ref. 68 ). Micrographs with poor estimated resolutions were eliminated at this point. Initially, 8,610 particles were picked from the first 28 micrographs by using the Laplacian-of-Gaussian picking function in RELION-3 (ref. 69 ) and were used to generate two-dimensional (2D) models for referencebased particle picking. A total of 635,921 particles were subsequently picked from the 1,575 micrographs in the first session (dataset 1) and extracted with a downsampling to a pixel size of 3.42 Å per pixel. These particles were subjected to rounds of 2D and 3D classifications to select 186,605 good particles, which were then reextracted with a pixel size of 1.33 Å per pixel and subjected to 3D refinement using a soft mask covering the LAT1-CD98hc-MEM-108 Fab and micelle. The resulting 3D model and particle set were subjected to per-particle CTF refinement, beam-tilt refinement and Bayesian polishing in RELION-3. The 1,807 micrographs from the second session (dataset 2) were processed similarly until particle polishing. A total of 361,967 polished particles from the two datasets were then joined and subjected to a 3D refinement yielding a map with a global resolution of 3.46 Å according to the FSC = 0.143 criterion 70 . To eliminate the adverse effects of the strong signals from the digitonin micelles, we performed a focused refinement. To do this, a mask covering only the protein region was prepared by using the volume eraser function in UCSF Chimera 71 . A mask covering only the micelle belt was prepared similarly and was used to subtract the density corresponding to the micelle belt from individual particles. A 3D refinement using the subtracted particles resulted in a nominal resolution of 3.28 Å. To further improve the map of the TMD, a 3D classification without alignment was performed by focusing on the TMD, resulting in one class (250,712 particles) with a better density at the TMD. These particles were used for a final 3D refinement, which yielded a map with a nominal resolution of 3.31 Å with improved map interpretability at the TMD (Supplementary Note 1) . Local resolutions were estimated from two unfiltered half maps, using RELION-3.
For the LAT1-CD98hc-HBJ127 Fab-MEM-108 Fab dataset, motion correction and CTF estimation were performed using MotionCor2 and CTFFIND4, and subsequent image processing was done with RELION-2.1. Initially, the 2D references for particle picking were generated through rounds of manual/ automatic particle picking and 2D classification. A total of 1,054,573 particles were subsequently picked from 1,354 micrographs and extracted with a downsampled pixel size of 3.54 Å per pixel. After 2D classifications, 267,070 particles were selected and extracted with an original pixel size of 1.49 Å per pixel. A 3D classification without any mask yielded a class containing 98,475 homogeneous particles, which were then used for 3D refinement, yielding a 5.05-Å map. This map had good density at the soluble regions (the ED and two Fabs) but little interpretable density at the TMD. To better resolve the ED and Fabs, we applied a mask covering only the ED and two Fabs. By using this mask, the original 267,070 particles were subjected to a 3D classification, yielding two classes with homogeneous orientations of the two Fabs relative to the ED. The 160,553 particles belonging to these classes were used for a 3D refinement with a mask covering the ED and Fabs, generating the final 4.1-Å map (Supplementary Note 2).
and EMPIAR-10265. Source data for Fig. 3d,e and Supplementary Figs. 1d-g and 5a-c are available online. All other data are available from the corresponding author upon request.
